Back to search

Article

Evaluation of Symptom and Side Effect Bother in Cutaneous T-cell Lymphoma Patients Treated with Mogamulizumab or Vorinostat

2021-06-08

Abstract excerpt

<title>Abstract</title> <p><bold>Background:</bold> Cutaneous T-cell lymphomas, including mycosis fungoides or Sézary syndrome, are rare non-Hodgkin lymphomas that can be serious and life-threatening with significant morbidity and impaired quality of life. The purpose of this study was to determine whether patient-reported outcome individual items on skin symptoms and toxicity bother show significant treatment di...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
72f9bf71-cffc-5139-802a-221e7d73502b
DOI
10.21203/rs.3.rs-566715/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Evaluation of Symptom and Side Effect Bother in Cutaneous T-cell Lymphoma Patients Treated with Mogamulizumab or VorinostatDOI 10.21203/rs.3.rs-566715/v1
Biologic Treatment for Cutaneous Immune-Related Adverse Events in Cancer Patients Undergoing Immune-Checkpoint Therapy: A Retrospective ReviewSemantic proximity
Cutaneous immune-related adverse events are associated with longer overall survival in advanced cancer patients on immune checkpoint inhibitors: a multi-institutional cohort studySemantic proximity
Treatment Modality as a Key Predictor of Quality of Life Impairment in Chronic Dermatological DiseasesSemantic proximity
Understanding and managing anti-MDA 5 dermatomyositis, including potential COVID-19 mimicrySemantic proximity
Topical resiquimod can induce disease regression and enhance T-cell effector functions in cutaneous T-cell lymphomaSemantic proximity
Pre-Existing Inflammatory Disease Predicts Cutaneous Immunotherapy Toxicity Development: A Multi-Institutional Cohort StudySemantic proximity
The heightened impact of COVID-19 on emotional wellbeing and delays in care in patients with cutaneous T-cell lymphoma: A cross-sectional studySemantic proximity
Perceptions of patient disease burden and management approaches in systemic mastocytosis: Results of the TouchStone Healthcare Provider Survey.Semantic proximity
Clinical Spectrum, Quality of Life, BRAF Mutation Status and Treatment of Skin Involvement in Adult Langerhans Cell Histiocytosis.Semantic proximity
A retrospective analysis of drugs associated with the development of cutaneous squamous cell carcinoma reported by patients on the FDA’s adverse events reporting systemSemantic proximity
Validation and Responsiveness of the English version of the Chemotherapy-Induced Alopecia Distress Scale (CADS) in Breast Cancer PatientsSemantic proximity
Cutaneous adverse events associated with Rybrevant based on FDA Adverse Event Reporting System (FAERS) database from 2021 to 2024Semantic proximity
Select a neighboring publication to make it the new centre.